{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:22:35Z","timestamp":1791264155584,"version":"4.1.0"},"reference-count":109,"publisher":"Impact Journals, LLC","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,10,30]]},"DOI":"10.18632\/oncotarget.2465","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T23:37:39Z","timestamp":1442360259000},"page":"9564-9576","source":"Crossref","is-referenced-by-count":49,"title":["Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia"],"prefix":"10.18632","volume":"5","author":[{"given":"Angelika","family":"Berger","sequence":"first","affiliation":[{"name":"Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Sexl","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Hematology and Ludwig-Boltzmann Cluster Oncology, Medical University of Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moriggl","sequence":"additional","affiliation":[{"name":"Ludwig-Boltzmann Institute for Cancer Research, University of Veterinary Medicine, Medical University Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,10,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Darnell","year":"2012","journal-title":"Immunity"},{"key":"2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1534-5807(02)00376-3","article-title":"The Jak\/STAT pathway in model organisms: emerging roles in cell movement","volume":"3","author":"Perrimon","year":"2002","journal-title":"Dev Cell"},{"key":"3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2302\/kjm.58.73","article-title":"Regulation of cytokine signaling by the SOCS and Spred family proteins","volume":"58","author":"Yoshimura","year":"2009","journal-title":"Keio J Med"},{"key":"4","first-page":"104","article-title":"The role of Stat5 transcription factors as tumor suppressors or oncogenes","volume":"1815","author":"Moriggl","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cytogfr.2004.09.001","article-title":"STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5","volume":"15","author":"Silvennoinen","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"6","doi-asserted-by":"crossref","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Waters","year":"2014","journal-title":"Science"},{"key":"7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nsmb.2807","article-title":"Structural basis of recognition of interferon-\u03b1 receptor by tyrosine kinase 2","volume":"21","author":"Lupardus","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"8","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1073\/pnas.0501063102","article-title":"Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle","volume":"102","author":"Darnell","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1101\/gad.11.2.179","article-title":"Stat5a is mandatory for adult mammary gland development and lactogenesis","volume":"11","author":"Hennighausen","year":"1997","journal-title":"Genes Dev"},{"key":"10","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1073\/pnas.94.14.7239","article-title":"Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression","volume":"94","author":"Davey","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","article-title":"Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation","volume":"107","author":"Sexl","year":"2006","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bbadis.2013.05.022","article-title":"Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities","volume":"1832","author":"Pulido","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/107999001750277844","article-title":"Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway","volume":"21","author":"Miller","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"16520","DOI":"10.1074\/jbc.M210572200","article-title":"Identification of Shp-2 as a Stat5A phosphatase","volume":"278","author":"Wang","year":"2003","journal-title":"J Biol Chem"},{"key":"15","doi-asserted-by":"crossref","first-page":"39718","DOI":"10.1074\/jbc.M005615200","article-title":"A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b","volume":"275","author":"Matsuda","year":"2000","journal-title":"J Biol Chem"},{"key":"16","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Perrotti","year":"2013","journal-title":"J Clin Invest"},{"key":"17","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2006-07-036335","article-title":"Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage","volume":"109","author":"Tomasson","year":"2007","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2006-05-024018","article-title":"Activation mechanisms of STAT5 by oncogenic Flt3-ITD","volume":"110","author":"Serve","year":"2007","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood.V95.6.2076","article-title":"Transforming properties of chimeric TEL-JAK proteins in Ba\/F3 cells","volume":"95","author":"Bernard","year":"2000","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Van Etten","year":"2012","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Sexl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"e97243","DOI":"10.1371\/journal.pone.0097243","article-title":"BCR-ABL affects STAT5A and STAT5B differentially","volume":"9","author":"Eder","year":"2014","journal-title":"PLoS One"},{"key":"23","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-12-3955","article-title":"Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem\/progenitor cells","volume":"73","author":"Dusanter-Fourt","year":"2013","journal-title":"Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Van Etten","year":"1996","journal-title":"J Biol Chem"},{"key":"25","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Larson","year":"2009","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Sawyers","year":"2001","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-642-01222-8_7","article-title":"Dasatinib","volume":"184","author":"Hochhaus","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Ottmann","year":"2006","journal-title":"N Engl J Med"},{"key":"29","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Gambacorti-Passerini","year":"2006","journal-title":"Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Superti-Furga","year":"2009","journal-title":"Leukemia"},{"key":"31","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1158\/1078-0432.CCR-13-0258","article-title":"Ponatinib-a step forward in overcoming resistance in chronic myeloid leukemia","volume":"19","author":"Licht","year":"2013","journal-title":"Clin Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Rousselot","year":"2010","journal-title":"Lancet Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/emmm.201100208","article-title":"Diverging fates of cells of origin in acute and chronic leukaemia","volume":"4","author":"Beug","year":"2012","journal-title":"EMBO Mol Med"},{"key":"35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Druker","year":"2011","journal-title":"J Clin Invest"},{"key":"37","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","article-title":"Autocrine TNF-\u03b1 production supports CML stem and progenitor cell survival and enhances their proliferation","volume":"122","author":"Holyoake","year":"2013","journal-title":"Blood"},{"key":"38","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2013-07-517847","article-title":"The IL-2\/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells","volume":"123","author":"Suda","year":"2014","journal-title":"Blood"},{"key":"39","article-title":"PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene","author":"Huang","year":"2014","journal-title":"Blood"},{"key":"40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Scapozza","year":"2003","journal-title":"Lancet Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Sexl","year":"2011","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.18632\/oncotarget.806","article-title":"STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia","volume":"3","author":"Sexl","year":"2012","journal-title":"Oncotarget"},{"key":"43","first-page":"87","article-title":"Stat5 tetramer formation is associated with leukemogenesis","author":"Beug","year":"2005","journal-title":"Cancer Cell"},{"key":"44","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","article-title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia","volume":"121","author":"Mustjoki","year":"2013","journal-title":"Blood"},{"key":"45","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","author":"Elenitoba-Johnson","year":"2014","journal-title":"Blood"},{"key":"46","article-title":"Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia","author":"Heckman","year":"2014","journal-title":"Leukemia"},{"key":"47","article-title":"The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse","author":"Kulozik","year":"2014","journal-title":"Haematologica"},{"key":"48","article-title":"Frequent STAT5B mutations in \u03b3\u03b4 hepatosplenic T-cell lymphomas","author":"Raffeld","year":"2014","journal-title":"Leukemia"},{"key":"49","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V99.8.2637","article-title":"Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways","volume":"99","author":"Tweardy","year":"2002","journal-title":"Blood"},{"key":"50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.20042541","article-title":"Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis","volume":"202","author":"Nakauchi","year":"2005","journal-title":"J Exp Med"},{"key":"51","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2006-01-029918","article-title":"Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias","volume":"109","author":"Gouilleux","year":"2007","journal-title":"Blood"},{"key":"52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2013.098442","article-title":"Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy","volume":"99","author":"Arock","year":"2014","journal-title":"Haematologica"},{"key":"53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/leu.2013.192","article-title":"STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention","volume":"28","author":"Johnson","year":"2014","journal-title":"Leukemia"},{"key":"54","article-title":"PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis","author":"Sexl","year":"2013","journal-title":"Leukemia"},{"key":"55","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Frank","year":"2011","journal-title":"Blood"},{"key":"56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1947601912466555","article-title":"The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations","volume":"3","author":"Frank","year":"2012","journal-title":"Genes Cancer"},{"key":"57","doi-asserted-by":"crossref","first-page":"e90275","DOI":"10.1371\/journal.pone.0090275","article-title":"The synthetic \u03b1-bromo-2\u2032,3,4,4\u2032-tetramethoxychalcone (\u03b1-Br-TMC) inhibits the JAK\/STAT signaling pathway","volume":"9","author":"Rascle","year":"2014","journal-title":"PLoS One"},{"key":"58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ab.2008.01.017","article-title":"A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization","volume":"375","author":"Berg","year":"2008","journal-title":"Anal Biochem"},{"key":"59","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/jm200720n","article-title":"Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity","volume":"55","author":"Gunning","year":"2012","journal-title":"J Med Chem"},{"key":"60","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","author":"Deininger","year":"2014","journal-title":"Leukemia"},{"key":"61","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Skoda","year":"2005","journal-title":"N Engl J Med"},{"key":"62","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"Vainchenker","year":"2005","journal-title":"Nature"},{"key":"63","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Gilliland","year":"2005","journal-title":"Cancer Cell"},{"key":"64","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-07-4839","article-title":"Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers","volume":"14","author":"Lee","year":"2008","journal-title":"Clin Cancer Res"},{"key":"65","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/asheducation.V2012.1.389.3798360","article-title":"The molecular genetic makeup of acute lymphoblastic leukemia","volume":"2012","author":"Mullighan","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"66","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","article-title":"JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia","volume":"122","author":"Sexl","year":"2013","journal-title":"Blood"},{"key":"67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Sexl","year":"2012","journal-title":"Nat Chem Biol"},{"key":"68","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Holyoake","year":"2012","journal-title":"Blood"},{"key":"69","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2009.299","article-title":"Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors","volume":"24","author":"Hughes","year":"2010","journal-title":"Leukemia"},{"key":"70","article-title":"Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2","author":"Sexl","year":"2014","journal-title":"Leukemia"},{"key":"71","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/stem.1711","article-title":"Critical role of jak2 in the maintenance and function of adult hematopoietic stem cells","volume":"32","author":"Mohi","year":"2014","journal-title":"Stem Cells"},{"key":"72","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo","author":"Holyoake","year":"2014","journal-title":"Blood"},{"key":"73","first-page":"3589","article-title":"Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells","volume":"56","author":"Hallek","year":"1996","journal-title":"Cancer Res"},{"key":"74","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1038\/sj.onc.1204807","article-title":"Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway","volume":"20","author":"Takahara","year":"2001","journal-title":"Oncogene"},{"key":"75","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","article-title":"The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells","volume":"21","author":"Skorski","year":"2002","journal-title":"EMBO J"},{"key":"76","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606","volume":"111","author":"Bhatia","year":"2008","journal-title":"Blood"},{"key":"77","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Bhatia","year":"2008","journal-title":"Cancer Res"},{"key":"78","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1038\/onc.2012.369","article-title":"Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells","volume":"32","author":"M\u00fcller-Newen","year":"2013","journal-title":"Oncogene"},{"key":"79","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Superti-Furga","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"80","first-page":"3043","article-title":"Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation","volume":"17","author":"Moriggl","year":"2011","journal-title":"Front Biosci"},{"key":"81","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2009-12-258913","article-title":"Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation","volume":"116","author":"Moriggl","year":"2010","journal-title":"Blood"},{"key":"82","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.immuni.2012.10.017","article-title":"CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response","volume":"38","author":"Kovarik","year":"2013","journal-title":"Immunity"},{"key":"83","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.celrep.2013.07.012","article-title":"CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance","volume":"4","author":"Sexl","year":"2013","journal-title":"Cell Rep"},{"key":"84","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00280-012-1839-5","article-title":"Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies","volume":"69","author":"Grant","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"85","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1172\/JCI67509","article-title":"Pak and Rac GTPases promote oncogenic KIT-induced neoplasms","volume":"123","author":"Kapur","year":"2013","journal-title":"J Clin Invest"},{"key":"86","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ccr.2007.10.015","article-title":"Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease","volume":"12","author":"Williams","year":"2007","journal-title":"Cancer Cell"},{"key":"87","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/leu.2008.71","article-title":"Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis","volume":"22","author":"Williams","year":"2008","journal-title":"Leukemia"},{"key":"88","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2009-10-247437","article-title":"Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo","volume":"116","author":"Cancelas","year":"2010","journal-title":"Blood"},{"key":"89","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/leu.2012.351","article-title":"Contributions of the RhoGEF activity of p210 BCR\/ABL to disease progression","volume":"27","author":"Whitehead","year":"2013","journal-title":"Leukemia"},{"key":"90","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1128\/MCB.01423-08","article-title":"A Rac GTPase-activating protein, MgcRacGAP, is a nuclear localizing signal-containing nuclear chaperone in the activation of STAT transcription factors","volume":"29","author":"Kitamura","year":"2009","journal-title":"Mol Cell Biol"},{"key":"91","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1083\/jcb.200604073","article-title":"Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors","volume":"175","author":"Kitamura","year":"2006","journal-title":"J Cell Biol"},{"key":"92","doi-asserted-by":"crossref","first-page":"24175","DOI":"10.1074\/jbc.M414044200","article-title":"ERBB4\/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events","volume":"280","author":"Jones","year":"2005","journal-title":"J Biol Chem"},{"key":"93","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0303-7207(01)00546-9","article-title":"Role of serine phosphorylation of Stat5a in prolactin-stimulatedbeta-casein gene expression","volume":"183","author":"Rui","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"94","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1074\/jbc.275.14.10247","article-title":"Stat5a serine phosphorylation. Serine 779 is constitutively phosphorylated in the mammary gland, and serine 725 phosphorylation influences prolactin-stimulated in vitro DNA binding activity","volume":"275","author":"Hynes","year":"2000","journal-title":"J Biol Chem"},{"key":"95","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1128\/MCB.16.10.5691","article-title":"Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype","volume":"16","author":"Gouilleux","year":"1996","journal-title":"Mol Cell Biol"},{"key":"96","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1128\/MCB.18.4.1783","article-title":"Characterization of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocortiocoid receptor in mammary cells","volume":"18","author":"Hynes","year":"1998","journal-title":"Mol Cell Biol"},{"key":"97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1083\/jcb.200407163","article-title":"Getting the message across, STAT! Design principles of a molecular signaling circuit","volume":"167","author":"Vinkemeier","year":"2004","journal-title":"J Cell Biol"},{"key":"98","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1038\/emboj.2011.287","article-title":"Ran-dependent nuclear export mediators: a structural perspective","volume":"30","author":"G\u00f6rlich","year":"2011","journal-title":"EMBO J"},{"key":"99","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1083\/jcb.200403057","article-title":"Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1","volume":"165","author":"Vinkemeier","year":"2004","journal-title":"J Cell Biol"},{"key":"100","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4155\/fmc.11.121","article-title":"Inhibition of Ras for cancer treatment: the search continues","volume":"3","author":"Der","year":"2011","journal-title":"Future Med Chem"},{"key":"101","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nature12830","article-title":"Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness","volume":"504","author":"Morrison","year":"2013","journal-title":"Nature"},{"key":"102","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1074\/jbc.M111.334524","article-title":"Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase","volume":"287","author":"Dharmawardhane","year":"2012","journal-title":"J Biol Chem"},{"key":"103","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1073\/pnas.0307512101","article-title":"Rational design and characterization of a Rac GTPase-specific small molecule inhibitor","volume":"101","author":"Zheng","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"104","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/fon.11.143","article-title":"Targeting Rho GTPase signaling for cancer therapy","volume":"8","author":"Baugh","year":"2012","journal-title":"Future Oncol"},{"key":"105","doi-asserted-by":"crossref","first-page":"40782","DOI":"10.1074\/jbc.M507682200","article-title":"Structure of the unphosphorylated STAT5a dimer","volume":"280","author":"Becker","year":"2005","journal-title":"J Biol Chem"},{"key":"106","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4161\/jkst.21232","article-title":"Acetylation and sumoylation control STAT5 activation antagonistically","volume":"1","author":"Moriggl","year":"2012","journal-title":"JAK-STAT"},{"key":"107","unstructured":"http:\/\/www.sanger.ac.uk\/research\/projects\/cancergenome\/."},{"key":"108","unstructured":"http:\/\/clinicaltrials.gov\/show\/NCT01702064."},{"key":"109","unstructured":"http:\/\/clinicaltrials.gov\/show\/NCT01751425."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T10:29:46Z","timestamp":1599560986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,9]]},"references-count":109,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2014,10,30]]}},"alternative-id":["2465","25333255"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2465","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,9]]}}}